Reversed-phase HPLC assay for plasminogen activators
Patent Information
- Application Number
- HU2002002973
- Authority / Receiving Office
- HU · HU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2000-11-01
- Filing Date
- 2000-11-01
- Publication Date
- 2005-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods are inadequate for efficiently separating and quantifying recombinant human tissue plasminogen activator (tPA) from endogenous Chinese hamster ovary (CHO) cell-derived plasminogen activator (CHO-PA) due to their similar biochemical properties and the complexity of glycoprotein characterization.
A reversed-phase HPLC method involving protease-mediated cleavage of the Arg275-Ile276 bond, followed by denaturing and reducing agents, and subsequent high-performance liquid chromatography to analyze the elution profile for CHO-PA levels.
Effectively separates and quantifies recombinant tPA and its variants from CHO-PA, reducing heterogeneity and improving the purity assessment of tPA preparations for clinical and commercial production.
Description
(54) Reversed-phase HPLC assay for plasminogen activators (57) Extract The invention describes a method for monitoring the efficiency of a purification process in which plasminogen activator (PA) endogenous to Chinese hamster ovary (CHO) cells is removed from a sample containing human tPa or variants thereof. This method involves incubating the sample with a protease capable of specifically cleaving the Arg275-Ile275 bond of human wild-type tPA, followed by denaturing / reducing agents in an amount sufficient to reduce the disulfides of human wild-type tPA, and further comprising subjecting the resulting sample to a reversed-phase high-performance liquid chromatography step, and analyzing the elution profile obtained from the chromatography step for the amount of PA endogenous to CHO cells present. EN 226 202 B1 The description is 12 pages long (including 3 pages of illustrations). EN 226 202 B1 The invention is directed to the determination of the amount of Chinese Hamster Ovary (CHO)-produced tPA present in samples of recombinant human tPA with native sequence or its variants produced in CHO cells. The state of the art is described below. Tissue-type plasminogen activators (tPA) are endogenous serine proteases involved in the cascade of events leading to the dissolution of blood clots [Astrup and Permin: Natúré 159, 681-682 (1947); Camiolo et al.: Proc. Soc. Exp. Biol. Med. 138, 277-280 (1971); Collen: J. Biol. Chem. 33, 76-86 (1987); Hoylaerts et al.: J. Biol. Chem. 257, 2912-2919 (1982)]. Activase (ACTIVASE) is a recombinant form of human tPA (r-tPA) used in the treatment of acute myocardial infarction and pulmonary embolism. [Grossbard: Pharm. Res. 4, 375-378 (1987)]. Activase is also approved for the treatment of ischemic stroke [Smith et al. Acad. Emergency Medicine 6(6), 618-25 (1999); Kwiatkowski et al. New. Eng. J. Med. 340(23), 1781-1787 (1999)]. It is a glycoprotein produced by the expression of complementary DNA (cDNA) to native human tPA in Chinese hamster ovary (CHO) cells.TNK-tPA is a genetically engineered version of human tPA that is cloned and expressed in CHO cells [Keyt et al. Proc. Natl. Acad. Sci. USA 91, 3670-3674 (1994)]. Site-directed mutations are introduced at three specific sites in human tPA to generate the TNK-tPA variant. These are Thr103 to Asn (T103N), Asn 117 to Gln (N117Q), and Lys-His-Arg-Arg 296-299 to Ala-Ala-AlaAla (KHRR296-299-AAAA). When compared to tPA, TNK-tPA exhibits similar in vitro biological activity, increased resistance to plasminogen activator inhibitor and enhanced fibrin specificity, and is cleared from plasma much more slowly [Keyt et al. Proc. Natl. Acad. Sci. USA 91, 3670-3674 (1994); Thomas et al. Stroke 25(10), 2072-2079 (1994); Benedict et al. Circulation 92(10), 3032-3040 (1995); Módi et al. Thromb. Haemost. 79, 134-139 (1998)]. It is currently awaiting regulatory approval for a single-dose formulation of r-tPA.CHO cells biosynthesize endogenous hamster tPA, termed CHO-PA. CHO-PA has similar fibrinolytic activity to human tPA, as determined by a blood clotting assay. The amino acid sequence of CHO-PA is 80% identical to that of human tPA. Most of the substitutions are semiconservative, such as Arg<->Lys, Glu<->Asp, PheTyr, Val<->Ala, Ile<->Leu, or Thr<->Ser. Using a model of the protease domain of human tPA based on the structure of bovine chymotrypsin, it is observed that almost all of the substitutions in CHO-PA are localized at or near the protein surface. r-tPA, TNK-tPA and CHO-PA all form a single polypeptide chain consisting of 527 amino acids with 17 disulfide bonds [Nguyen and Carole: Stability Characterization and Formulation Development of Altepase, a Recombinant Tissue Plasminogen Activator), in Stability and Characterization of Protein and Peptide Drugs: Case Histories, edited by Wang YJ and Pearlman R., published by Plenum Press, New York (1993), pp. 91-135.]. In all three proteins, the peptide bond between Arg275 and Ile276 is particularly susceptible to protease cleavage. Cleavage results in two fragments: one containing the N-terminal 275 amino acids and the other containing the C-terminal 252 amino acids. The N-terminal chain contains regions that are homologous to the "kringle" regions found in plasminogen and prothrombin, and are therefore often referred to as "kringle fragments" [Nguyen and Carole, supra; de Vos et al., Biochem. 31, 270-279 (1992)]. The C-terminal chain contains the catalytically active site and is therefore often referred to as the "protease fragment". [Pennica et al. Nature 301, 214-221 (1983)]. The two cleaved chains are linked by a unique disulfide bridge formed between Cys264 and Cys395. The cleaved molecule is commonly referred to as a mini "two-chain tPA", in contrast to "single-chain tPA" or the intact form. r-tPA contains four potential sites for N-linked glycosylation, identified by the sequence Asn-X-Ser / Thr (Nguyen and Carole, op. cit.). These are Asn117, Asn184, Asn218, Asn448. r-tPA exists as two glycosylation isozymes, referred to as type I and type II isozymes. Type I r-tPA is glycosylated at Asn117, Asn184, and Asn448, while type II r-tPA is glycosylated only at Asn117 and Asn448. Asn218 is not glycosylated in either isoform. TNK-tPA has the same glycosylation pattern as r-tPA, except that the Thr103->Asn and Asn117->Gln mutations effectively shift the glycosylation site from position 117 to position 103 (Keyt et al., supra). The glycosylation pattern of CHO-PA has not yet been fully characterized (Rijken and Collen, J. Biol. Chem. 256, 7035-7041 (1981)). ACTIVASE is the trademarked name for a recombinant form of human tissue-type plasminogen activator (r-tPA), which is used to treat acute myocardial infarction and pulmonary embolism. ACTIVASE trademarked tPA is also approved for the treatment of ischemic stroke. It is produced by expressing the complementary DNA (cDNA) of natural human tPA in Chinese hamster ovary (CHO) cells (see U.S. Patent No. 5,753,486). TNK-tPA is a genetically modified version of r-tPA with increased efficacy and a reduced incidence of bleeding compared to ACTIVASE r-tPA. It was constructed by three site-directed mutations (T103N, N117Q, and KHRR296-299AAAA) and was also cloned and expressed in CHO cells (see U.S. Patent No. 5,612,029). CHO cells biosynthesize an endogenous hamster tPA, termed CHO-PA. The amino acid sequence of CHO-PA is highly HU 226 202 Β1 is homologous (80% identity) to the amino acid sequence of r-TPA. All three thrombolytic proteins exist in heterogeneous isoforms, largely due to proteolysis / hydrolysis and differential glycosylation. U.S. Patent No. 5,411,864 describes a process for purifying human tPA from CHO-PA. The process includes contacting a liquid containing human tPA with antibodies that specifically bind to the corresponding endogenous CHO-PA and recovering the human tPA. The contacting step preferably includes passing the liquid over a chromatographic bed having the antibodies immobilized thereon. The development of recombinant DNA-derived protein drugs has been facilitated by the introduction of new analytical techniques that can be used to characterize proteins and / or demonstrate the composition of a protein in a preparation. Peptide mapping is a key technique for following the amino acid sequence and can detect small changes in protein size, such as insulin and human growth hormone. However, the analysis of a much larger protein, such as fibrinogen (molecular weight 350,000), or heterogeneous glycoproteins such as antibodies (molecular weight 150,000), is hampered by the complexity of the range of peptides generated by enzymatic digestion. Such complexity makes single-phase high-performance liquid chromatography separations combined with on-line ultraviolet detection of limited utility. The advent of commercially available combined HPLC and electrospray ionization mass spectrometry (LC-ES-MS) systems, which are compatible with conventional HPLC, has significantly increased the efficiency of peptide mapping [Ling et al. Anal. Chem. 63, 2909-2915 (1991); Guzetta et al. Anal. Chem. 65, 2953-2982 (1993)]. LC-EM-MS combined with in-source collisionally-induced dissociation (CID) has been effectively used to identify N- and O-linked glycosylation sites [Carr et al. Protein Sci. 2, 183-196 (1993); Huddleston et al. Anal. Chem. 65, 877-814 (1993); Conboy and Henion: J. Am. Soc. Mass Spectrom. 3, 804-884 (1992)]. Even these techniques are limited by insufficient resolution, which is a consequence of the large number of very similar peptides, and this is caused by variable protein glycosylations and enzymatic digestions of moderately sized glycoproteins.Therefore, a series of techniques with orthogonal selectivity must be applied to characterize these samples. The use of combinations of high-performance capillary electrophoreses, HPLC, LC-ES-MS and matrix-assisted laser desorption ionization-time of flight mass spectrometry was investigated to enable the characterization of enzymatic digests of non-derivatized samples, using as an example DSPA a1, a single-chain plasminogen activator derived from vampire bat salivary glands (Apffel et al., J. Chromatography A 717, 41-60 (1995)). It was concluded that these four techniques are highly complementary techniques for the study of glycoproteins. However, the authors agree that much work needs to be done to improve the efficiency of this approach and that high-throughput concentration steps are required due to the extensive carbohydrate heterogeneity. There is therefore a need for a suitable technique for monitoring the relative and absolute amounts of CHO-PA after performing a purification procedure for tPA, such as that described in U.S. Patent No. 5,411,864. The invention is briefly summarized below. We developed a reversed-phase HPLC method for the analysis of three thrombolytic molecules, CHO-tPA, native sequence recombinant human tPA, and TNK-tPA. This method is not only capable of separating human tPA and / or TNK-tPA from CHO-PA, but also of identifying and quantifying different isoforms of each molecule. More specifically, the invention provides a method for monitoring the effectiveness of a purification process for removing endogenous plasminogen activator (PA) in Chinese hamster ovary (CHO) cells from a sample containing human tPA or variants thereof, which method comprises incubating the sample with a protease capable of specifically cleaving the Arg275-He276 bond of human wild-type tPA, followed by denaturing and reducing agents in amounts effective to reduce the disulfide bonds of human wild-type tPA, followed by subjecting the sample to a reversed-phase high-performance liquid chromatography step, and analyzing the elution profile resulting from the chromatography step for the amount of endogenous PA present in the CHO cells. The figures are briefly described below. Figure 1 shows the reversed-phase HPLC analysis of native r-tPA, TNK-tPA, and CHO-PA. Figure 2 shows the reverse phase HPLC analysis of DTT / urea treated r-tPA, TNK-tPA and CHO-PA. Plasminogen activators are treated with DTT / urea prior to chromatography. Figure 3 shows the reverse phase HPLC analyses of r-tPA, TNK-tPA and CHO-tPA treated with plasmin and DTT / urea. The plasminogen activators are subjected to plasmin treatment following DTT / urea treatment before chromatography. Preferred embodiments will be described below. Definitions The terms “tissue plasminogen activator” and “tPA” refer to human exogenous (tissue-type) plasminogen HU 226 202 refers to a β1 activator with fibrinolytic activity and typically has a structure with five domains (finger, growth factor, kringle-1, kringle-2 and protease domains), but may have fewer domains or some of its domains may be repetitive if it is still able to function as a thrombolytic agent and retains N-linked glycosylation sites at positions 117, 184 and 448. At a minimum, tPA contains a protease domain capable of converting plasminogen to plasmin and an N-terminal region believed to be at least partially responsible for fibrin binding and retains N-linked glycosylation sites at positions corresponding to positions 117, 184 and 448 of wild-type human tPA. The retention of these glycosylation sites is attributed to the fact that the occupancy of the variable site by recombinant and melanoma-derived wild-type tPA leads to the formation of two variants, referred to as “type I tPA” and “type II tPA”.We call this type of tPA “type I”. Type I tPA contains N-linked oligosaccharides at positions 117, 184 and 448. Type II tPA contains N-linked oligosaccharides at positions 117 and 448. It is understood that natural allelic variations exist and may occur between individuals, as evidenced by one or more amino acid differences in the amino acid sequence of each individual’s tPA. The terms "wild-type human tissue plasminogen activator," "wild-type human tPA," "native human tissue plasminogen activator," and "native human tPA," where the term "human tPA" may also be abbreviated as "htPA," refer to native sequence human tPA, i.e., that encoded by the cDNA sequence disclosed in U.S. Patent No. 4,766,075 (issued August 23, 1988). The amino acid positions or sites in the tPA molecule are designated in accordance with U.S. Patent No. 4,766,075. As used herein, references to different domains of tPA refer to the domains of wild-type human tPA as defined above and to functionally equivalent portions of human tPA with amino acid changes compared to the native human IPA sequence or to functionally equivalent portions of a tPA sequence from another source (native or variant), such as bat tissue plasminogen activator (bat-PA), [as used herein, the term "protease domain" refers to a region extending from amino acid position 264 to amino acid position 527 (inclusive) of the mature form of wild-type human tPA and refers to functionally equivalent portions of human tPA with amino acid changes compared to the native human tPA sequence or to functionally equivalent portions of a tPA sequence from another source, such as bat-PA. As used herein, the term "tPA variants" refers to molecules that differ from native tPA by one or more amino acid changes or modifications relative to the existing amino acids. A preferred variant herein is TNK-tPA. Modification to alter or delete the appropriate amino acid or amino acids in the native molecule to create the desired sequence variants can be accomplished by methods known in the art, such as site-directed mutagenesis or ligating the appropriate sequence into the DNA encoding the protein of interest. As used herein, the term "TNK-tPA" refers to a tPA molecule in which Thr 103 of wild-type tPA is changed to Asn (T103N), Asn117 of wild-type tPA is changed to Gln (N117Q), and Lys-HisArg-Arg 296-299 of wild-type are changed to Ala-Ala-Ala-Ala (KHRR296-299-AAAA). Such TNK is described in detail in U.S. Patent No. 5,612,029. The term "Chinese hamster ovary cells" or "CHO cells" refers to cells or cell lines derived from Chinese hamster ovaries, as described, for example, in the following references: European Patent Application EP 117,159 (published August 29, 1989); U.S. Patents 4,766,075; U.S. Patents 4,853,330 and 5,185,259; Lubiniecki et al., in Advances in Animal Cell Biology and Technology for Bioprocesses (eds. Spier et al., 1989), pp. 442-451; the term also refers to CHO derivatives such as CHO / -DHFR cells [Urlaub and Chasin: Proc. Natl. Acad. Sci., USA 77, 4216 (1980)3, CHO-K1 DUX B11 cells [Simonsen and Levinson: Proc. Natl. Acad. Sci. USA 80, 2495-2499 (1983); Urlaub and Chasin: supra], and dp12. CHO cells [European Patent Application No. EP 307,247 [published March 15, 1989]]. Preferred host cells are CHO-K1 DUX B11 and dp12. CHO cells. CHO cells developed for large-scale production of tPA are cryogenically maintained in an MCB / working cell bank (WCB) system as described by Wiebe et al. [in Large Scale Mammalian Cell Culture Technology; Lubiniecki, ed.; Marcel Dekker, New York (1990), pp. 147-160]. DHFR+CHO-K1 cells transfected with DNA encoding human tPA are deposited with the American Type Culture Collection (ATCC), Manassas, Virginia, USA, and are available under accession number CCL 61. A sample of another tPA-producing CHO cell line (1-15i5CHO cell line) is deposited with the ATCC under accession number CRL-9606. The latter cell line has been reported to produce human tPA levels approaching 50 pg / cell / day. As used herein, the terms "CHO plasminogen activator" or "CHO-PA" refer to a plasminogen activator that is endogenously produced by CHO cells. This endogenous PA expressed by CHO cells has a slightly different sequence (approximately 80% identical) from human wild-type tPA. CHO-PA is not a tissue-type PA. As used herein, the term "protease" refers to an enzyme capable of specifically cleaving hu4 HU 226 202 Β1 man binding to Arg275-lle276 of wild-type tPA. Examples of these include plasmin (or plasminogen converted to plasmin), tissue kallikrein, or factor Xa, and any trypsin-like protease capable of carrying out this specific, limited proteolysis. Suitable proteases are also described by Ichinosi et al. [FEBS Letters 175, 412-418 (1984)]. Plasmin / plasminogen is preferred here. As used herein, the terms "denaturing / reducing agent" or "denaturing agent and reducing agent" refer to a combination of denaturing agents and reducing agents that reduce the disulfide bonds of human wild-type tPA. The denaturing agent is preferably guanidine or urea, and the reducing agent is dithiothreitol (DTT) or 2-mercaptoethanol. Ways of carrying out the invention After recombinant production, the tPA or tPA variant is recovered from the CHO culture medium either as a secreted protein or from the host cell lysate when directly expressed without a selection signal. It is also necessary to purify the tPA or variant from the host cell proteins to obtain preparations that are substantially homogeneous as proteins. As a first step, the culture medium or lysate is centrifuged or filtered to remove cellular debris. The human tPA or variant is then purified from appropriate contaminating endogenous proteins, such as CHO-PA, by techniques such as fractionation on immunoaffinity or ion exchange columns, such as those described in U.S. Patent No. 5,411,864; ethanol precipitation; reverse phase HPLC; chromatography on silica gel or cation exchange resins such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation or gel electrophoresis using, for example, Sephadex G-75. It may also be useful to use a protease inhibitor that does not interfere with tPA activity; such as phenylmethylsulfonyl fluoride (PMSF); this protease inhibitor inhibits proteolytic degradation during purification. Antibiotics may also be included in the purification process to prevent the growth of potentially infectious agents.Those skilled in the art will appreciate that purification procedures suitable for native tPA may require modifications to take into account the changes in the character of tPA and its variants that occur when expressed in recombinant cell culture. In a preferred embodiment, when a tPA variant is produced, it is isolated and the supernatant is passed through a PBS-preconditioned column of glass beads bound to anti-tPA goat polyclonal A6 antibody, where the column is equilibrated with a buffer, and the tPA variant is then eluted. The invention is directed to monitoring levels of native CHO-PA in samples from such purification systems (including qualitative and quantitative monitoring), wherein the system comprises at least one form of human tPA produced in CHO cells. The method comprises incubating the sample with a protease that is specifically capable of cleaving the Arg275-Ile276 bond. This is followed by incubating the protease-treated sample with a combination of a denaturing and reducing agent in relative and absolute amounts sufficient to effect reduction of disulfide bonds in human wild-type tPA. Since treatment with the denaturing and reducing agents results in a loss of enzyme activity, the incubation with the protease is performed first. After incubation, the sample is subjected to a reversed-phase high-performance liquid chromatography step, and the elution profile obtained from the chromatography step is analyzed for the amount of PA endogenous to the CHO cells used herein. The protease is preferably plasminogen, which is converted to the active form, i.e. plasmin; the human tPA is native sequence tPA, and the tPA variant is TNK-tPA. The successive incubation steps with protease and then denaturing / reducing agents typically occur at about 30°C-40°C, preferably about 38°C, and most preferably about 40°C for a minimum of 15 minutes, preferably about 20-40 minutes. Prior to incubation, the sample is preferably diluted with a digestion buffer, preferably having a pH of between about 7 and 8, and more preferably a phosphate buffer having a pH of between 7.4 and 7.6, which preferably also contains arginine. Any suitable HPLC column on which the sample is loaded can be utilized for the purposes of the invention, including both preparative and analytical scales. The column is typically equilibrated for at least 15 minutes prior to sample injection. The column size, column material, flow rate, elution buffers, gradient type, injection volume, and column particle size depend on various factors, including the size of the sample to be analyzed, the composition and gradient type of the mobile phase, and the forms of tPA to be separated. The loading solvent may be any solvent, but is preferably an acetonitrile-based solvent, such as water, acetonitrile, and trifluoroacetic acid (TFA). The column is preferably a Zorbax C8, Vydac, or Baker C-18 column, packed with a medium having a particle diameter of about 4-40 pm, preferably 5-15 pm, and a pore size of about 100-4000 angstroms, preferably about 150-350 angstroms. The medium preferably has a C4, C8, or C18 alkyl group, but is most preferably a C8 silica medium. Elution is preferably performed with a solvent containing acetonitrile, such as water, acetonitrile, and TFA, in a gradient configuration, preferably a linear gradient, over a period of 60-100 minutes, wherein the relative amount of acetonitrile in the solvent increases in the gradient. In another preferred embodiment, a shallow gradient is used at about 0.25% acetonitrile / minute. If the purity analysis indicates that the technique used successfully removes CHO-PA, additional purification steps can be performed, if necessary, to remove additional contaminants. If the technique does not successfully remove CHO5 EN 226 202 B1 PA to appropriate levels, a different cleaning schedule can be utilized, and the process is repeated to determine how effective that schedule is. After final purification, the tPA or variant can be formulated according to known methods to produce pharmaceutically useful compositions; for this purpose, the tPA product is combined in admixture with a pharmaceutically acceptable carrier. Such formulations are well described in the literature, as are dosages and uses, for example, tPA or variants thereof can be suitably administered parenterally to patients suffering from cardiovascular diseases or conditions, or stroke. The following examples are intended to illustrate an embodiment known in the practice of the invention, but are not to be construed as limiting the scope of the invention. All references to open and patent literature cited herein are hereby expressly incorporated by reference. Example 1 Materials ACTIVASE (r-tPA) and TNK-tPA are obtained from Genentech, Inc. (South San Francisco, California, USA) in a form purified from CHO cells. See, for example, U.S. Patents 4,766,075 and 5,753,486 [for ACTIVASE r-tPA], and U.S. Patent 5,612,029 (for TNK-tPA). A monoclonal antibody (#354) to CHOPA is prepared as described in U.S. Patent No. 5,411,864. Briefly, a female Balb / c mouse is immunized for 12 weeks with a protein solution significantly enriched in CHO plasminogen activator purified from host cells lacking human t-PA. This involves five injections, each containing approximately 30 pg. The initial injection is emulsified with complete Freund's adjuvant and administered subcutaneously. The second injection, given 1.5 weeks later, is emulsified with incomplete Freund's adjuvant and administered half subcutaneously and half intraperitoneally. The remaining three injections are given at weeks 3, 6, and 12 in phosphate-buffered saline (PBS), administered into an intraperitoneal site. The spleen of the immunized mouse is removed at week 13 and splenocytes are fused with the NP3X63-Ag8.653 murine myeloma cell line using the general procedure of Fazekas et al. [J. Immunol. Methods 35, 1 (1980)] and Lane [J. Immunol. Methods 81, 223 (1985)]. The fused cells are distributed into 10 microtiter plates, each containing 96 wells. Each well is screened for specific antibody production using differential reactivity in two ELISAs (enzyme-linked immunosorbent assays). One ELISA specifically detects antibodies to CHO-PA, and the other ELISA detects antibodies that cross-react with recombinant human tPA. Approximately 5% of all wells are reactive with CHO-PA only, and 3% react with CHO-PA and human tPA. Hybridoma cells are plated from wells containing antibodies specific for CHO-PA and cloned by limiting dilution [Oi and Herzenberg, Immunoglobin-Producing Hybrid Cell Lines, in Selected Methods in Cellular Immunology, edited by Mishell and Shiigi, published by WH Freeman and Co. (1980), pp. 351-372]. Large quantities of specific monoclonal antibodies can be produced by cell culture of hybridoma cells or by injecting hybridoma cells into mice, which develop ascites tumors. MAb 354 is one of the antibodies that has been developed that reduces CHO-PA levels by more than about one-hundredth when passed through a single column when immobilized thereon, and is stable under a variety of different immobilization chemistries and harsh washing conditions. MAb 354 is purified using the following procedure, with all steps performed at room temperature. Concentration is performed as follows: the harvest fluid (HF) of the MAb hybridoma suspension culture is filtered through a 0.2 µm filter. The culture fluid is concentrated by ultrafiltration or ion exchange resin chromatography. Affinity purification is performed as follows. Thimerosal is added to the concentrated MAb-HF solution at approximately 0.02%. The solution is adjusted to approximately 1.5 mol / l glycine, 3.0 mol / l NaCl and pH=9.0 by adding 3.0 mol / l glycine and then crystalline NaCl. Protein A has weak Ab binding, so the addition of NaCl and glycine increases the hydrophobic interaction, making Ab binding easier. The solution is clarified by filtration. The clarified, concentrated MAb is applied to a column of protein A, which is immobilized on agarose. The bound MAb is washed with buffer used to equilibrate the column, which has an approximate composition of 1.5 mol / l glycine, 3.0 mol / l NaCl, 0.02 mol / l EDTA (pH=9.0). The MAb is eluted with a buffer containing 0.1 mol / L sodium citrate and 0.15 mol / L NaCl (pH=3.0). The protein A column is regenerated by washing with a solution containing 3.0 mol / L NaSCN and 0.03 mol / L Tris (pH=8.5) and re-equilibrated.The eluted MAb peaks are collected based on the absorbance profile measured at 280 nm. The citrate eluted MAb peak is immediately neutralized by collecting it in a buffer with the approximate composition of 1.5 mol / L Tris.HCl (pH=9.0). After use, the Protein A column is emptied and stored in sealed containers at 2-8 °C in approximately 0.02% thimerosal as storage buffer. The 354 MAb is then buffer exchanged by diafiltration. Diafiltration is continued until the conductivity and pH are similar to those of 0.03 mol / L Tris, 0.05 mol / L NaCl (pH=8.5). EN 226 202 B1 The MAb is then applied to an anion exchange column containing DEAE-FAST FLOW agarose support and washed with a solution containing 0.03 mol / L Iris and 0.05 mol / L NaCl (pH=8.5). The MAb is then eluted stepwise with a buffer having an approximate concentration of 0.03 mol / L Tris, 0.15 mol / L NaCl (pH=8.5). The eluted MAb peak is collected based on the absorbance profile obtained at 280 nm. The MAb is filtered (0.2 µm) into sterilized sealable containers and stored below -40°C. Plasminogen was purchased from Fluka (Switzerland). HPLC-grade acetonitrile was purchased from Burdick & Jackson (Muskgon, Michigan), and trifluoroacetic acid (TFA) was purchased from Pierce (Rockford, Illinois). Water for HPLC mobile phase and sample solutions were purified using a MILLI-Q system from Millipore (Milford, Massachusetts). All other chemicals were reagent-grade from Sigma (St. Louis, Missouri). Procedures Purification of CHO-PA CHO-PA was isolated from CHO cell culture fluid by affinity chromatography followed by immunoabsorption. Lysine hyper D resin from BioSepra (Paris, France) was used for affinity chromatography because lysine binds to the kringle 2 domain of plasminogen activators [Cleary et al., Biochem. 28, 1884-1890 (1989)]. Immunoabsorption was performed using CHO-PA-specific monoclonal antibody #354 (MAb #354). MAb #354 was coupled to CNBr-activated SEPHAROSE 4B gel according to the manufacturer's protocol (Pharmacia Biotech, Piscataway, New Jersey). Approximately 10 mg of MAb #354 was coupled to 1 ml of CNBr-activated Sepharose 4B gel. After coupling, the MAb #354-SEPHAROSE 4B column is loaded. The CHO cell culture fluid containing the selected CHO-PA is loaded onto a lysine affinity column that has been pre-equilibrated with equilibration buffer containing 50 mmol / L sodium phosphate and 0.01% POLYSORBATE 80 detergent (pH=7.5). After loading, the lysine affinity column is washed three times: first with the equilibration buffer, then with a buffer containing 40 mmol / L Tris, 800 mmol / L NaCl and 0.008% POLYSORBATE 80 (pH=8.0), and finally with the equilibration buffer again. The CHO-PA is then eluted from the lysine affinity column with a buffer containing 50 mmol / L sodium phosphate, 200 mmol / L arginine and 0.01% POLYSORBATE 80 (pH=7.5). After equilibration with phosphate-buffered saline (PBS; 8 g / L NaCl, 0.2 g / L KCl, 1.44 g / L Na2HPO4, and 0.24 g / L KH2PO4, pH=7.4), the MAb #354-SEPHAROSE 4B column is loaded with the elution pool from the lysine affinity column.After loading, the column is washed with a buffer containing 9.5 mmol / L Na2HPO4, 1 mol / L NaCl and 5% propylene glycol (pH=7.4). Bound CHO-PA is eluted from the column with 0.2 mol / L glycine.HCl (pH=2.5). Elution is monitored spectrophotometrically at 280 nm and CHO-PA-containing fractions are neutralized with 0.14 volumes of 1.5 mol / L arginine phosphate (pH=8.0) immediately after collection. The identity and purity of the eluted CHO-PA are determined. It is identified by SDS-PAGE and amino acid sequence analysis. DTT / carbamyl treatment The solution containing the plasminogen activator(s) is diluted 1:1 (v / v) with denaturing buffer [8 mol / l urea, 0.5 mol / l Tris and 3.2 mmol / l EDTA (pH=8.4)]. Dithiothreitol (DTT) is added from a 1 mol / l stock solution to a final concentration of 20 mmol / l and the mixture is incubated at 37 °C for 30 minutes. Plasmin treatment The solution containing the plasminogen activator(s) is diluted 1:3 (v / v) with digestion buffer [125 mmol / L Na2HPO4, 200 mmol / L arginine, and 0.01% NaN3 (pH=7.5)]. 100 μl (w / w) of plasminogen is added and the mixture is incubated at 37 °C for 30 minutes. Reversed-phase HPLC assay for plasminogen activators The assay was performed on a Hewlett-Packard 1090M HPLC system (Hewlett Packard, Avondale, Pennsylvania) with a 4.6 mm x 25 mm, 5 μm particle size, 300 angstrom pore size resin on a Zorbax SB-C8 column (Mac-Mod, Chadds Ford, Pennsylvania). The column was equilibrated for at least 15 minutes before sample injection. The initial mobile phase composition was 70 / 30 / 0.1 (v / v / v) water / acetonitrile / TFA. After a 5-minute initial delay, a linear gradient was developed to 50 / 50 / 0.1 (v / v / v) water / acetonitrile / TFA over 80 minutes (Figures 1 and 2) and 60 minutes (Figure 3). Immediately after the gradient, the column is regenerated for 10 minutes with 100 / 0.1 (v / v) acetonitrile / TFA. The composition is then brought back to the original conditions for 5 minutes and the system is re-equilibrated for the next injection. The injection volume is 250 ml and the flow rate is 1 ml / min. The chromatography is carried out at 40 °C.Fluorescence was measured using a Hewlett-Packard 1046A programmable fluorescence detector (Ex=275 nm, and Em=340 nm). Chromatograms were recorded and analyzed using Hewlett-Packard CHEMSTATION software. Results and discussion Due to their high sequence homology, ACTIVASE (r-tPA), TNK-tPA and CHO-PA have very similar biochemical / biophysical properties. Analytical and preparative methods capable of separating these three plasminogen activators from each other or capable of separating tPA from CHOPA or TNK-tPA from CHO-PA are needed to develop recovery procedures and estimate the purity of each molecule for clinical studies and commercial scale production. Here we describe a simple reversed-phase HPLC method that fulfills these goals. With a flat gradient slope at 0.25% acetonitrile / min and without protease and denaturing / reducing agents, the reverse HU 226 202 Phase Β1 HPLC is unable to separate the native form of r-tPA from native CHO-PA (Figure 1). However, the native form of TNK-tPA is very well separated from both native r-tPA and CHO-PA under these conditions. A DTT / urea treatment is then performed to reduce disulfide bonds and denature the proteins. In all three proteins, the peptide bond between Arg275 and lle276 is very susceptible to protease cleavage. Over time, this susceptibility leads to heterogeneity in r-tPA, TNK-tPA, and CHO-PA in solution. A small amount of the single-chain form is converted to the double-chain form due to protease cleavage. DTT / urea treatment reduces the disulfide bond between Cys264 and Cys395, which holds the double-chain form together, and this results in the dissociation of the molecule into two fragments (the kringle fragment and the protease fragment). Figure 2 shows that with the same gradient slope, reversed-phase HPLC is able to separate the single-chain forms of the three thrombolytic molecules from each other after DTT / urea treatment. All three proteins show similar elution profiles, with the kringle fragment of the two-chain form eluting first, the single-chain form eluting second, and the protease fragment of the two-chain form eluting last. The corresponding protease fragments of the three plasminogen activators also separate well from each other, while the kringle fragments of the three molecules do not. Consequently, this method is suitable for detecting and quantifying the fragmentation of the single-chain form into the two-chain form of the plasminogen activators. The heterogeneity observed in the r-tPA, TNK-tPA and CHO-PA profiles (Figure 2) makes the quantitative assessment of these molecules very difficult, especially when attempting to quantify individual molecules in a mixture of r-tPA, TNK-tPA and CHO-PA. In order to eliminate the heterogeneity associated with proteolysis, all single-chain forms were converted to two-chain forms by incubation with plasminogen. Plasminogen is the substrate for plasminogen activator in the natural fibrinolytic system. Each of r-tPA, TNK-tPA and CHO-PA has enzymatic activity to cleave the Arg560-Val561 peptide bond of plasminogen. Such cleavage converts plasminogen to its active form, plasmin. Plasmin is a serine protease with low specificity and is able to cleave the Arg275-Ile276 peptide bond in r-tPA, TNKtPa and CHO-PA. As a result, incubation with plasminogen converts the single-chain form of the three plasminogen activators to the two-chain form. Following plasmin treatment, the samples are treated with DTT / urea to reduce the disulfide bonds and thus dissociate the two-chain form of the molecule into two separate fragments. Figure 3 shows the reversed-phase HPLC profiles for plasminogen activators treated with plasmin and DTT / urea. The corresponding protease fragments of the three proteins are very well separated from each other, while the kringle fragments of the three molecules are not separated. Therefore, the protease fragment is used for the integration and quantification of each plasminogen activator. For both r-tPA and TNK-tPA, the kringle fragments from the type I and type II isozymes are very well separated. As a result, this method is suitable for the quantitative assessment of the type I / type II ratio for both r-tPA and TNK-tPA. The availability of this reversed-phase HPLC method greatly facilitates the development of the manufacturing process. It can be used to evaluate the effect of different fermentation conditions on product quality in terms of product integrity (i.e., percentage of unique chains), and the ratio of type I to type II isozymes. It can be used to aid in the development of the purification process and to ensure uniformity between production batches. All of these applications illustrate the key role of analytical and manufacturing processes in the development of new drugs.
Claims
1. A method for monitoring the efficiency of a purification process for removing endogenous plasminogen activator (PA) from a sample containing human tPA or variants thereof, comprising incubating the sample with a protease capable of specifically cleaving the Arg275-Ile276 bond of human wild-type tPA, followed by incubating the sample with a denaturing agent and a reducing agent in an amount effective to reduce the disulfide bonds of human wild-type tPA, subjecting the resulting sample to a reversed-phase high-performance liquid chromatography step, and finally analyzing the elution profile obtained from the chromatography step for the amount of PA endogenous to the CHO cells present.
2. The method according to claim 1, characterized in that plasminogen is used as protease.
3. The method of claim 1, wherein the human tPA is native sequence tPA.
4. The method of claim 1, wherein the tPA variant is TNK-tPA.
5. The method of claim 1, characterized in that the sample is diluted with digestion buffer before incubation.
6. The method according to claim 5, characterized in that the buffer used is a buffer with a pH value of about 7-8.
7. The method according to claim 6, characterized in that phosphate buffer is used as buffer.
8. The method according to claim 7, characterized in that a buffer containing arginine is used as the buffer.
9. The method according to claim 1, characterized in that the denaturing agent used is a denaturing agent containing urea or guanidine.
10. The process according to claim 1, characterized in that a reducing agent comprising dithiothreitol or 2-mercaptoethanol is used as the reducing agent.
11. The method of claim 1, wherein the chromatography step is carried out by eluting with a solvent comprising acetonitrile in a gradient composition.
